Summary:
Eli Lilly received FDA approval for its oral GLP-1 weight-loss drug Foundayo (orforglipron), marking the start of competition in the oral obesity drug market.
The drug was approved in just 50 days, setting a record for the fastest approval of a new molecular entity since 2002
Foundayo is a once-daily oral pill with no food or water restrictions, priced from $25/month (insured) to $149–$349/month (self-pay), and will be distributed via LillyDirect and retail channels.
Clinical data show Foundayo delivers ~12.4% weight loss, lower than injectable drugs like Zepbound (>20%) and also below Novo Nordisk’s oral Wegovy (~16.6%).
Eli Lilly and Novo Nordisk are entering a new “oral GLP-1 competition phase”, with both pricing similarly but differing in convenience (Wegovy requires fasting conditions).
The global obesity drug market is shifting to a dual-track model (oral + injectable), where efficacy, price, and convenience will drive competition and expand patient adoption.